rAAV2tYF-GRK1-RPGR

BIOLOGICAL2 trials

Sponsors

Beacon Therapeutics

Conditions

X-Linked Retinitis Pigmentosa

Phase 1

Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations

Active, not recruitingNCT03316560

Beacon TherapeuticsX-Linked Retinitis Pigmentosa

Start: 2018-04-16End: 2025-03-31Updated: 2024-05-20

Phase 2

A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)

Active, not recruitingNCT06333249

Beacon TherapeuticsX-Linked Retinitis Pigmentosa

Start: 2021-04-13End: 2027-02-28Updated: 2024-08-12

Related Papers

Systematic Identification of Candidate Genes for Inherited Retinal Disease Gene Therapy Integrating Worldwide IRD Cohort and Single-Cell Analysis.

2025-06-12

Viral Vector Technologies and Strategies: Improving on Nature

International Ophthalmology Clinics2021-07-015 citations